

Consent Form for the Protocol:

Antiseptic Effects on the Dental Implant Internal Surface Microbiome

NCT05024760

May 12, 2023

**MADIGAN ARMY MEDICAL CENTER
CONSENT TO PARTICIPATE IN RESEARCH &
AUTHORIZATION TO USE AND DISCLOSE
PROTECTED HEALTH INFORMATION FOR RESEARCH**

1
2 **PRINCIPAL INVESTIGATOR:** Kevin Smith, DMD | Department of Oral Maxillofacial
3 Surgery, Madigan Army Medical Center | kevin.d.smith2.mil@health.mil | 253-968-
4 0181

5
6 **KEY INFORMATION FOR PROTOCOL:** Antiseptic Effects on the Dental Implant
7 Internal Surface Microbiome

8
9 You are invited to take part in a research study. Your participation is voluntary. This page
10 gives you key information about the study to help you decide whether to participate.
11 Detailed information follows this page. Ask the researchers questions you have. If you
12 have questions later, the contact information for the research investigator is below.

13
14 **WHAT ARE THE PURPOSE, PROCEDURES, AND DURATION OF THE STUDY?**

15 We hope to learn if applying antiseptic to the inside of a dental implant will decrease or
16 alter the types of bacteria inside it. This may decrease the incidence of implant failure
17 associated with bone loss, infection, and other complications. During implant placement,
18 we will apply an antiseptic (chlorhexidine wash or hydrogen peroxide gel) or no
19 antiseptic to the inside of your new dental implant before covering it with a cover screw
20 or healing abutment. 3-6 months later, when we remove the hardware, we will swab the
21 implant's internal cavity. Your participation in this research will last about 3-6 months
22 and require one additional minute during implant insertion and hardware exchange.

23
24 **WHAT ARE THE KEY REASONS YOU MIGHT CHOOSE TO PARTICIPATE IN THIS
STUDY (BENEFITS)?**

25 The benefits of participation in this study include possible decreased risk of 1) damage
26 to adjacent teeth and 2) implant failure due to bone loss, infection, or other
27 complications. The procedure may also decrease the risk of additional surgeries such
28 as explantation of the implant and bone grafting, delaying the need for additional care or
29 tooth replacement.

30
31 **WHAT ARE THE KEY REASONS YOU MIGHT CHOOSE NOT TO PARTICIPATE IN
THIS STUDY (RISKS AND ALTERNATIVES)?**

32 The risks of participating in this study include the possibility of hypersensitivity to
33 chlorhexidine or hydrogen peroxide, Allergic reaction to chlorhexidine wash or peroxide
34 oral gel including itching, burning, swelling, mouth irritation, oral lesion, and oral mucosa
35 ulcer may occur.

36
37 **DO YOU HAVE TO TAKE PART IN THIS STUDY?**

40 If you decide to take part in the study, it should be because you really want to volunteer.
41 You will not lose any services, benefits or rights you would normally have at Madigan
42 Army Medical Center if you choose not to volunteer.

43

44 **WHAT IF YOU HAVE QUESTIONS, SUGGESTIONS, OR CONCERNS?**

45 The person in charge of this study is Kevin Smith. If you have questions, suggestions or
46 concerns about the study, his contact information is: 253-968-0181, and mailing address:
47 Madigan Army Medical Center, 9040 Jackson Avenue, Tacoma, WA 98431.

48

49 If you have any questions about your rights as a research subject or if you have concerns
50 or complaints about the research, please contact the Madigan IRB Office at: 253-968-
51 0149, Department of Clinical Investigation, 9040 Jackson Avenue, Tacoma, WA 98431-
52 1100.

53

54 Please tell the researchers if you are taking part in another research study.

55

56 If you decide to take part in this research study, you will be asked to sign this document.
57 Before you sign this document, be sure you understand what the research study is
58 about in all sections of the consent form, including the risks and possible benefits to
59 you.

60

61

62

63

DETAILED CONSENT:

64

1. WHAT IS THE PURPOSE AND DURATION OF THIS RESEARCH AND WHO WILL TAKE PART?

65 You are being asked to take part in this research study because you have missing teeth
66 and chose implant therapy to replace missing teeth. The purpose of this research study
67 is to learn about the bacteria of the internal cavity of the implant and how our methods
68 influence implant success. Your participation will require one additional minute during
69 implant insertion and one additional minute during hardware removal (3-6 months after
70 implant insertion).

71

72 There will be about 200 people taking part in the study at Madigan Army Medical
73 Center's Oral Maxillofacial Surgery Clinic, over a period of 1-2 years.

74

75 During the study, there are no additional visits needed. During implant placement, you
76 may or may not have chlorhexidine wash or peroxide gel placed inside the dental
77 implant. This will add less than one minute to your procedure time.

78

79 At the end of this research study the clinical results, including research results about
80 you will not be shared with you.

81

2. SCREENING PROCESS TO QUALIFY FOR PARTICIPATION IN THIS STUDY

82 Before you can take part in this study, you will need to provide some information so that
83 the Investigator can confirm that you qualify for the study. This is called the "Screening
84 Process". These tests may have been done or this information collected as a part of
85 your regular medical care. The screening process includes clinical chart review and
86 health physical assessment. This is the same screening used for all dental implant
87 patients.

88

3. WHAT WILL HAPPEN IF YOU DECIDE TO BE IN THIS RESEARCH?

89 During implant placement, we will apply an antiseptic (none, chlorhexidine wash, or
90 hydrogen peroxide gel) inside the implant then cover the implant with a cover screw or
91 healing abutment. 3-6 months later, we will recover/remove the hardware and culture
92 the bacteria that are inside of the implant with a swab. This process takes less than one
93 minute to complete.

94

95 You will be randomly assigned to one of 3 groups. Randomization is a process like
96 flipping a coin and means you will have a chance (33%) of being assigned to any of the
97 3 groups. Groups include 1- no treatment, 2-chlorhexidine wash, and 3-hydrogen
98 peroxide gel applied to the inside of the implant.

99

4. WHAT ARE THE RISKS OR DISCOMFORTS FROM BEING IN THIS RESEARCH?

100 If you choose to take part in this study, there is a risk of hypersensitivity to chlorhexidine
101 or hydrogen peroxide, possible microlleakage which may cause irritation and chemical
102 burns, and delayed wound healing. There are no known additional risks associated with
103 this study.

109 Although efforts are made to protect your research study records, there is always a risk
110 that someone could get access to the personal information in your medical records or
111 other information researchers have stored about you.

112 There may also be other risks of taking part in this study that we do not yet know about.
113

114 **5. WHAT ARE THE POSSIBLE BENEFITS FROM THIS RESEARCH?**

115 The possible benefits to you as a research participant in this research study include
116 possible decreased incidence of both damage to adjacent teeth and implant failure
117 associated with bone loss, infection, or other complications. It may also decrease the
118 risk of additional surgeries such as explantation of the implant and bone grafting,
119 ultimately delaying care and tooth replacement. However, there is no guarantee that
120 you will benefit from being in this research.
121

122 **6. WHAT ARE THE ALTERNATIVES TO TAKING PART IN THIS RESEARCH?**

123 Choosing not to take part in this research study is also an option.
124

125 **7. IS THERE COMPENSATION FOR YOUR PARTICIPATION IN THIS RESEARCH?**

126 No, you will not receive any compensation for participating in this study.
127

128 **8. ARE THERE COSTS FOR PARTICIPATING IN THIS RESEARCH?**

129 No, there are no costs to you for taking part in this research study.
130

131 **9. PRINCIPAL INVESTIGATOR (the person(s) responsible for the scientific and**

132 technical direction of the study): Kevin Smith, DMD
133

134 **10. STUDY SPONSOR (the organizations or persons who oversee the study and**

135 are responsible for analyzing the study data): None
136

137 **11. SOURCE OF FUNDING:** Advanced Medical Technology Initiative Extended
138 Innovation Fund; Madigan Army Medical Center, Department of Clinical Investigation
139

140 **12. LOCATION OF THE RESEARCH:** Madigan Army Medical Center, JBLM, WA 98431
141

142 **13. WHO WILL SEE MY INFORMATION (PRIVACY) AND HOW WILL IT BE**

143 PROTECTED (CONFIDENTIALITY)?
144

145 Records of your participation in this research study may only be disclosed in
146 accordance with state and federal law, including the Federal Privacy Act, 5 U.S.C.552a,
147 and its implementing regulations. DD Form 2005, Privacy Act Statement - Military
148 Health Records, contains the Privacy Act Statement for the records. A copy of DD
149 Form 2005 can be given to you upon request, or you can read on-line at:
150 <http://www.dtic.mil/whs/directives/infomgt/forms/eforms/dd2005.pdf>.
151

152 The research team will keep your research records. These records may be looked at by
153 staff from the Madigan Army Medical Center Human Research Protections Office
154

155 (HRPO), the Institutional Review Board (IRB), and the DoD Higher Level Review as part
156 of their duties. These duties include making sure that the research participants are
157 protected. Confidentiality of your records will be protected to the extent possible under
158 existing regulations and laws but cannot be guaranteed.

159
160 Procedures to protect the confidentiality of the data in this study include but are not
161 limited to: Removal of personal information, computer and data file password protection,
162 and the restriction of access privileges to study personnel. All identifiable information
163 will be stored on computers secured by the government's firewalls. All hard copy data
164 will be stored in a HIPAA approved locked box/cabinet within a locked office. Only
165 approved study personnel will have access to these documents.

166
167 Researchers will make every effort to protect your privacy and confidentiality; however,
168 there are risks of breach of information security and information loss.

169
170 If applicable, a description of this clinical trial will be available on
171 <http://www.ClinicalTrials.gov> as required by U.S. Law. This web site will not include
172 information that can identify you. At most, the Web site will include a summary of
173 results. You can search this Web site at any time.

174
175 Complete confidentiality cannot be promised for military personnel, because information
176 regarding your health may be required to be reported to appropriate medical or
177 command authorities to ensure the proper execution of the military mission, including
178 evaluation of fitness for duty.

179
180 Only IRB approved study team members will have access to your records and agree to
181 safeguard your protected health information by using and disclosing it only as permitted
182 by you in this consent or as directed by state and federal law.

183
184 Information gained from your participation in this research study may be published in
185 literature, discussed for educational purposes, and used generally to further science.
186 You will not be personally identified; all information will be presented as anonymous
187 data.

188
189 **14. AUTHORIZATION TO USE AND DISCLOSE PROTECTED HEALTH**
190 **INFORMATION FOR THIS RESEARCH:** You are being asked for permission to use
191 and disclose your protected health information (PHI) for this research study. Protected
192 health information is defined as individually identifiable health information.

193
194 The Health Insurance Portability & Accountability Act of 1996, Public Law 104-191 (also
195 known as HIPAA), establishes privacy standards to protect your health information.
196 This law requires the researchers to obtain your authorization (by signing this
197 document) before they use or disclose your protected health information for research
198 purposes in the study listed above.

200 **WHAT PERSONAL IDENTIFIERS AND/OR PROTECTED HEALTH INFORMATION**
201 **(PHI) MAY BE USED AND DISCLOSED IN THIS RESEARCH?**

202
203 The identifiers and/or PHI collected, used, or disclosed are below:
204

<ul style="list-style-type: none">• <i>Names and DoD ID</i>• <i>Dates (except year) directly related to an individual such as birth date</i>	<ul style="list-style-type: none">• <i>Medical history</i>• <i>Surgical history</i>• <i>Laboratory results</i>• <i>Imaging results</i>
---	---

205 **HOW WILL YOUR PROTECTED HEALTH INFORMATION BE USED OR**
206 **DISCLOSED IN THIS RESEARCH?**

207 Your name and DoD ID are necessary to associate your lab results with your other data.
208 Dates are needed to determine if age impacts success rates or bacterial content.
209 Medical and surgical history may reveal if factors other than treatment affect surgical
210 outcomes. The lab results identify the bacteria inside the dental implant. The bone x-ray
211 imaging results taken at your 3-5 month post-implant follow up as part of standard of
212 care will be used determine if the implant was successful or not and to identify the
213 presence of peri-implantitis
214

215 The use and disclosure of your protected health information is necessary in order to be
216 able to conduct the research described. Records of your participation in this research
217 may only be disclosed in accordance with state and federal law, including the Privacy
218 Act (5 U.S.C. 552a) and the Health Insurance Portability and Accountability Act of 1996
219 (HIPAA) and its implementing regulations (45 CFR 160 & 164).
220

221 Note: Protected health information of military service members may be used or
222 disclosed without your authorization to military command authorities to ensure the
223 proper execution of the military mission, including evaluation of fitness for duty.
224

225 By signing this document, you give your permission for information gained from your
226 participation in this research to be published in medical literature, discussed for
227 educational purposes, and used generally to further medical science. You will not be
228 personally identified; all information will be presented as anonymous data.
229

230 **WITH WHOM MAY YOUR PROTECTED HEALTH INFORMATION BE SHARED**
231 **THROUGH THIS RESEARCH?**

232

- The Madigan Army Medical Center Institutional Review Board
- Madigan Army Medical Center or Department of Defense representatives
- State and Federal Government representatives, when required by law (such as the Food and Drug Administration (FDA))

233
234 Those listed above who are covered entities under HIPAA agree to safeguard your
235 protected health information by using and disclosing it only as permitted by you in this
236 Authorization or as directed by state and federal law.
237

242 You need to be aware that some parties receiving your protected health information
243 may not have the same obligations to safeguard your protected health information and
244 may re-disclose your protected health information to parties not named above. If your
245 protected health information is re-disclosed, it may no longer be protected by state or
246 federal privacy laws.

247
248 **You do not have to sign this document. If you decide not to sign this document:**

- 249 • It will not affect your treatment, payment or enrollment in any health plans or affect
250 your eligibility for benefits.
- 251 • You will not be allowed to participate in the research.

252
253 **After signing this document, you can change your mind and:**

- 254 • Notify the principal investigator in writing that you have withdrawn your permission to
255 disclose or use your protected health information (revoke the Authorization).
- 256 • Send your written letter to Kevin Smith, DMD. Madigan Army Medical Center, 9040
257 Jackson Avenue, Tacoma, WA 98431 to inform him of your decision. Your
258 revocation is not effective until your letter is received.
- 259 • Researchers may continue to use and disclose your PHI that was obtained before
260 your revocation became effective to the extent that the researchers have taken
261 action in reliance on your earlier authorization. Researchers may also continue to
262 use or disclose your PHI as necessary to maintain the integrity or reliability of the
263 current research, as, for example, to account for your withdrawal from the study, to
264 conduct misconduct investigations, or to report adverse events.
- 265 • If you withdraw the Authorization, you will not be allowed to continue to participate in
266 the research.

267
268 If you have not already received a copy of the brochure entitled "Military Health System
269 Notice of Privacy Practices," you may request one, or it is available on-line at:

270 [https://www.health.mil/Military-Health-Topics/Privacy-and-Civil-Liberties/HIPAA-
271 Compliance-within-the-MHS/Notice-of-Privacy-Practices](https://www.health.mil/Military-Health-Topics/Privacy-and-Civil-Liberties/HIPAA-Compliance-within-the-MHS/Notice-of-Privacy-Practices)

272
273 If you have any questions or concerns about your privacy rights, you should contact the
274 MAMC HIPAA Privacy Officer, 9040 Jackson Avenue, Tacoma, WA, 98431. Telephone:
275 253-968-1642.

276
277 This Authorization does not have an expiration date.

278
279 Your signature at the end of this document acknowledges that you authorize Madigan
280 Army Medical Center and IRB approved study team members to use and disclose your
281 Protected Health Information (PHI) collected about you for research purposes as
282 described above.

283
284 **15. USE OF INFORMATION AND SPECIMENS?**

285 During this research study, you could be asked to provide the following types of
286 samples (biological specimens): At the time of hardware removal, the internal cavity of
287 the dental implant will be swabbed.

288 All identifiers will be removed from your specimens.

289
290 Each specimen will be labeled with your unique participant ID, which can be linked back
291 to you only via a master key which will only be accessible by IRB approved study team
292 members. The Master Key will never be printed and will only be stored electronically on
293 a password protected CAC enabled government computer and protected by the DoD's
294 firewalls

295
296 Research will not include human whole genome sequencing.

297
298 Although research that uses your samples may lead to the development of new
299 inventions, products, or discoveries (some that might be patented and licensed), there
300 are no plans to share any potential profits with you.

301
302 While this study is on-going, your samples will be handled in accordance with this
303 study's protocol and applicable regulations at the following laboratory: Department of
304 Clinical Investigation, Madigan Army Medical Center, 9040 Jackson Avenue, JBLM,
305 WA, 98431.

306
307 The information and/or specimens that we obtain from you for this study will be
308 deposited in a repository titled: Antiseptic Effects on the Dental Implant Internal Surface
309 Microbiome. Your de-identified information and specimens may then be used for future
310 research studies or given to another investigator without getting additional permission
311 from you. It is also possible that in the future we may want to use or share study
312 information that might identify you. If we do, a review board will decide whether or not
313 we need to get additional permission from you.

314
315 Future studies using your samples or information will be limited to research involving
316 dental disease.

317
318 **If you do not want your information and/or specimens added to a repository for**
319 **future use you should not sign this consent form.**

320
321 **16. VOLUNTARY PARTICIPATION**

322 The decision to take part in this research study is completely voluntary on your part
323 which means you do not have to take part if you do not want to. You may also leave the
324 research study at any time. If you choose not to take part in this research study or if
325 you leave the study before it is finished, there will be no penalty or loss of benefits to
326 which you are otherwise entitled.

327
328 **17. WHAT HAPPENS IF I WITHDRAW FROM THIS RESEARCH?**

329 Should you choose to withdraw, you must notify the Principal Investigator, Kevin Smith,
330 in writing. If you decide to no longer participate in this research study, the researcher
331 will destroy your stored samples. Up and until the master key is destroyed, which
332 contains your identifiers, we will also destroy your associated data. After the master key

333 is destroyed, however, there will be no way to determine which records correspond to
334 your data.

335
336 If you are receiving treatment as part of this research study, you will no longer be
337 eligible for such research-related treatment. Contact your personal physician to discuss
338 medical treatment for your condition.

339
340 Please note that withdrawing your consent to participate in this research does not fully
341 revoke your HIPAA Authorization to use/disclose your protected health information. To
342 make that revocation, please send a letter to the principal investigator as discussed in
343 the HIPAA Authorization section above.

344
345 The principal investigator of this research study may terminate your participation in this
346 research study at any time if *he* determines this to be in your best interest, if you are
347 unable to comply with the procedures required, or if you no longer meet eligibility
348 criteria.

349
350 **18. WHAT IF NEW INFORMATION IS LEARNED DURING THE STUDY THAT MIGHT**
351 **AFFECT YOUR DECISION TO PARTICIPATE?**

352 We will tell you if we learn new information that could change your mind about staying in
353 the study. We may ask you to sign a new consent form if the information is provided to
354 you after you have joined the study.

355
356 **CONTACT INFORMATION:**

357
358 **Principal Investigator (PI):** The Principal Investigator or a member of the research
359 staff will be available to answer any questions throughout this study.

360
361 Principal Investigator: Kevin Smith, DMD
362 Phone: 253-968-0181
363 Mailing Address: Madigan Army Medical Center, 9040 Jackson Avenue, Tacoma, WA
364 98431.

365
366 **Madigan Human Research Protection Program (HRPP) Office:** The Human
367 Research Protection Program Office staff and/or Human Protections Director (HPD) will
368 be available to answer questions or discuss concerns you may have about this research
369 study. Please contact the Madigan HRPP Office at: 253-968-0149, Department of
370 Clinical Investigation, 9040 Jackson Avenue, Tacoma, WA 98431-1100.

371
372 IF THERE IS ANY PORTION OF THIS DOCUMENT THAT YOU DO NOT
373 UNDERSTAND, ASK THE INVESTIGATOR BEFORE SIGNING. YOU MAY CONSULT
374 WITH YOUR PERSONAL PHYSICIAN OR LEGAL ADVISOR, IF YOU WISH.

375
376 A signed and dated copy of this document will be given to you.

377

378
379

SIGNATURE OF PARTICIPANT

380

381 By signing below, I agree that I have been provided time to read the information
382 describing the research study in the consent form. The content and meaning of this
383 information has been explained to me. I have been provided with the opportunity to ask
384 questions. I voluntarily consent to participate in this study.

385

386 By signing this form, I have not given up any of my legal rights as a research participant.

387

388

389

390

391 Printed Name of Participant

392

393

394

395

396 Signature of Participant

Date

397

398

399

400

401

402

403

SIGNATURE OF INDIVIDUAL ADMINISTERING CONSENT

404 (Can only be signed by an investigator or staff approved to administer consent)

405

406

407

408

409

410

Printed Name of Administering Individual

411

412

413

414

Signature of Administering Individual

Date



IRB NUMBER: 222059
IRB APPROVAL DATE: 05/12/2023